Seattle, Washington — According to state and local economic development sources Sana Biotechnology plans to invest $1,819,452.00 to build out 17,700 square feet of new space in Seattle. The company plans to occupy the new space at 188 E Blaine St in Seattle, on or about October 1, 2021. According to the company website Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Sana launched in early 2019 and has approximately two hundred employees in Seattle, Cambridge, and South San Francisco. In 2019, we raised capital to enable our broad vision, began to acquire technology and establish an IP estate across cell and gene therapy, and made significant progress validating our cell and gene therapy platforms. Growing from this foundation, we intend to push forward our platforms and product pipeline in 2020 and beyond.

To learn more about Sana Biotechnology, visit http://sana.com/

Company Contact:
Steve Harr, Chief Executive Officer
steve.harr@sana.com
206-701-7914

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved